While women make up half the world’s population and own two out of every five businesses, there are substantial knowledge gaps about conditions affecting their health – mostly due to decades of ...

At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias ...

Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 ...

It’s difficult to fathom that the health of half the world’s population is underserved. But it’s a hard truth. There are many conditions that disproportionately impact women. Other conditions and ...

Eko Health Inc. recently won a category III CPT code for its Sensora platform for cardiovascular disease detection. While a “cat III” CPT code hasn’t traditionally excited industry, the company is ...

Artbio Inc. and 3B Pharmaceuticals GmbH have signed a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide α-radioligand therapy for the ...

Trex Bio Inc. has closed an oversubscribed $84 million series B financing round to support development of its pipeline of novel therapies that modulate the immune system to restore human tissue immune ...

MD Biopharm Co. Ltd. has identified compounds acting as mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) and kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the ...

Biontech SE is extending its relationship with Biotheus Inc. from a licensing deal to a full-scale acquisition, agreeing to pay $800 million cash and up to $150 million in milestone payments for the ...

WDR45 is located on the X chromosome. Its pathogenic variants are associated with various neurodegenerative disorders that are predominantly reported in females and present a wide range of clinical ...

The next-generation farnesyl transferase inhibitor KO-2806 is currently in phase I clinical development at Kura Oncology Inc. for the treatment of patients with solid tumors, including non-small-cell ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...